Geron Corporation
$1.39
(as of Jul 8, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Geron Corporation
Stock Price
$1.39
Ticker Symbol
GERN
Exchange
NASDAQ
Industry Information for Geron Corporation
Sector
Healthcare
Industry
Biotechnology
Company Description for Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Fundamentals for Geron Corporation
Market Capitalization
$910,792,704
EBITDA
$-133,736,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.21
Earnings per Share Estimate Next Year
Profit Margin
-119.54%
Shares Outstanding
636,918,016
Percent Owned by Insiders
0.09%
Percent Owned by Institutions
81.22%
52-Week High
52-Week Low
Technical Indicators for Geron Corporation
Analyst Ratings for Geron Corporation
Strong Buy
4
Buy
2
Hold
3
Sell
0
Strong Sell
0
News About Geron Corporation
Jun 18, 2025, 6:04 PM EST
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units (RSUs) representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employment with Geron.
See more.
May 23, 2025, 1:37 PM EST
The U.S. market is currently experiencing heightened volatility, with major indices like the Dow Jones and Nasdaq Composite facing declines due to renewed trade tensions following President Trump's recent tariff threats against the EU and Apple. See more.
May 15, 2025, 9:00 PM EST
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. See more.
May 13, 2025, 8:55 AM EST
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. See more.